# Icatibant (Firazyr)

> Bradykinin B2 receptor antagonist for hereditary angioedema attacks.

Source: https://peptides.cafe/peptide/icatibant
Category: Bradykinin Antagonist · Immunology
Tag: FDA-Approved · Rare Disease

## Mechanism
Synthetic decapeptide that competitively blocks the bradykinin B2 receptor, halting the vascular leak that drives HAE swelling attacks.

## Research areas
- Hereditary angioedema (acute attacks)

## Common research protocols
- Acute attack: 30 mg SC; repeat every 6h if needed (max 3 doses/24h).

## Study summaries
- "FAST-3 trial" — Annals of Allergy (2011): Faster symptom relief vs placebo in HAE attacks.

## Considerations
- FDA-approved.
- Injection-site reactions very common.

## Disclaimer
Educational content only. Not medical advice, diagnosis, or treatment. Most research peptides are not FDA-approved for human therapeutic use. Consult a licensed clinician before any use.